Sanofi Patient Connection
Sanofi-Aventis offers Sanofi Patient Connection, a comprehensive set of patient support services designed to facilitate access to Sanofi’s medications to patients who are unable to afford them.
Sanofi’s oncology and oncology supportive care drugs, their indications, and support services programs are listed in the Table.
SANOFI PATIENT Connection
Sanofi Patient Assistance Connection provides medication at no cost to patients who meet the program’s eligibility requirements. This support is made possible through the Sanofi Foundation for North America.
Reimbursement Connection helps patients and providers in determining insurance verification, prior authorization verification, coding and billing, and claims management and appeals assistance.
Resource Connection assists patients in finding additional resources and support, including clinical support services, transportation, and home care services support.
Sanofi Genzyme, together with Regeneron Pharmaceuticals, offer a wide range of patient support and access services through Libtayo Surround to eligible patients who have been prescribed Libtayo (cemiplimab-rwlc) injection. Libtayo Surround offers comprehensive patient support and 2 financial assistance options.
To be eligible for Sanofi Patient Connection, patients must:
- Be a US citizen or resident
- Be under the care of a US-licensed provider who is authorized to prescribe medicines
- Have no insurance coverage or no access to the prescribed drug or treatment through their insurance
- Have out-of-pocket total drug costs of 5% of their household’s annual income
- Have an annual household income of ≤500% of the poverty level
- Not be eligible for Medicare or Medicaid
- Patients enrolled in Medicare Part D can be assessed for eligibility if they are not eligible for Medicare’s low income subsidy, and do not have coverage for a generic drug equivalent.
Application & Enrollment
The application form for the Sanofi Patient Connection program is available online.
To enroll in the program, the completed application must be submitted by fax to 888-847-1797 or by mail to the address provided on the application form.
Applications can also be initiated by calling 888-847-4877. In addition, healthcare providers can use the secure provider portal to submit the application.
A licensed healthcare provider who is authorized to prescribe, dispense, and administer medicines in the United States must fill out and sign the application form and provide the prescribing information, including a diagnosis code. Proof of income is not required, and Sanofi Patient Connection will estimate patients’ income by using their date of birth, Social Security number, and/or additional demographic information to access their credit information.
Patients and their healthcare providers are notified of their eligibility and enrollment into the program. Patient eligibility is valid for up to 12 months, and patients may reapply on an annual basis for longer assistance with paying for their Sanofi medication.
Patients can enroll in the Libtayo Surround program by completing the Libtayo Surround Enrollment Form and faxing it to 833-853-8362, or by calling 877-542-8296.
Sanofi’s Resource Connection provides patient education and assists patients with finding additional resources to obtain help with access to clinical support services; transportation; health supply/cosmetic aids (eg, wigs, scarves); home care services support (eg, shelter, utilities); nutritional supplements (eg, groceries, food bank); and patient advocacy.
Leukine Direct Reimbursement Support Line
Sanofi provides patients who are prescribed Leukine (sargramostim) reimbursement consultants through the Leukine Direct Reimbursement Support Line. Patients and physicians can speak with reimbursement consultants by calling 888-479-5385.
Mozobil Reimbursement Assistance
For patients who are prescribed Mozobil (plerixafor injection), Sanofi offers reimbursement support through its Reimbursement Connection and Resource Connection programs. Click here for more information.
Table Sanofi-Aventis Oncology/Supportive Care Drugs